Menu Search
Equities

Divi's Laboratories Ltd

DIVISLAB:NSI

Divi's Laboratories Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)5,469.15
  • Today's Change26.20 / 0.48%
  • Shares traded213.58k
  • 1 Year change+44.88%
  • Beta0.5774
Data delayed at least 15 minutes, as of Sep 18 2024 11:28 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy2
Outperform3
Hold6
Sell5
Strong Sell6

Share price forecast in INR

The 22 analysts offering 12 month price targets for Divi's Laboratories Ltd have a median target of 4,437.50, with a high estimate of 5,740.00 and a low estimate of 3,000.00. The median estimate represents a -18.50% decrease from the last price of 5,445.00.
High5.4%5,740.00
Med-18.5%4,437.50
Low-44.9%3,000.00

Dividends

In 2024, Divi's Laboratories Ltd reported a dividend of 30.00 INR, equaling last years dividend. The 18 analysts covering the company expect dividends of 27.92 INR for the upcoming fiscal year, a decrease of 6.92%.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in INR

On Aug 04, 2024, Divi's Laboratories Ltd reported 1st quarter 2025 earnings of 16.20 per share.
The next earnings announcement is expected on Nov 04, 2024.
Average growth rate+7.68%
Divi's Laboratories Ltd reported annual 2024 earnings of 60.27 per share on May 25, 2024.
Average growth rate+10.67%
More ▼

Revenue history & estimates in INR

Divi's Laboratories Limited had 1st quarter 2025 revenues of 21.18bn. This bettered the 20.64bn consensus of the 12 analysts covering the company. This was 19.12% above the prior year's 1st quarter results.
Average growth rate+5.16%
Divi's Laboratories Limited had revenues for the full year 2024 of 78.45bn. This was 1.00% above the prior year's results.
Average growth rate+11.36%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.